DescriptionSources: https://www.medicines.org.uk/emc/medicine/20014Curator's Comment: Description was created based on several sources, including http://www.fkog.uu.se/course/a/biolakt/biolakt-archive/litteratur2011ht/tyrotricin_Marie.pdf and http://www.eurosurveillance.org/images/dynamic/EE/V20N34/art21215.pdf
Sources: https://www.medicines.org.uk/emc/medicine/20014
Curator's Comment: Description was created based on several sources, including http://www.fkog.uu.se/course/a/biolakt/biolakt-archive/litteratur2011ht/tyrotricin_Marie.pdf and http://www.eurosurveillance.org/images/dynamic/EE/V20N34/art21215.pdf
Tyrothricin is a mixture of non-ribosomal peptides produced by Brevibacillus brevis, now known as Aneurinibacillus migulanus, a gram positive aerobic bacteria. The compound mixture shows activity against bacteria, fungi and some viruses. A very interesting feature of AMPs is the fact, that even in vitro it is almost impossible to induce resistances. It is a locally effective antibiotic effective against gram-positive bacteria. It is sometimes combined with benzocaine 5 mg (Tyrozets) to provide relief from sore throats. Recommended for short-term relief of symptoms of oral and throat inflammation. Prevention of infections before/during mouth and throat operations (tooth extractions, gum surgical treatment). Tyrothricin inhibits protein biosynthesis of gram-positive organisms, but is completely ineffective against gram-negative.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Staphylococcus aureus growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/23955154 |
|||
Target ID: Plasmodium falciparum growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/20547797 |
0.05 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Tyrozets Approved UseAs an antibiotic and local analgesic-anaesthetic. For minor mouth and throat irritations; secondary irritation following tonsillectomy and other mouth and throat surgery. Launch Date2008 |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/17462586 |
Primary | Unknown Approved UseUnknown |
||
| Curative | Tyrosur Powder Approved UseIndications:
Surface wounds with insignificant release of exudate and with superinfection (erosive and ulcerous skin and mucous membrane lesions) caused by pathogenic microorganisms sensitive to Tyrothricin (infected eczema, purulent skin inflammations, burns). |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010. | 2014-02 |
|
| Suppressive effects of peptide antibiotics against proliferation and cytokine production in mitogen-activated human peripheral-blood mononuclear cells. | 2011 |
|
| Inhibition of malaria parasite blood stages by tyrocidines, membrane-active cyclic peptide antibiotics from Bacillus brevis. | 2007-06 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/medicine/20014
Curator's Comment: Can also be used topically for wounds treatment http://www.ndrugs.com/?s=tyrosur%20powder
Adults : 1 lozenge to be dissolved slowly in the mouth every three hours. Do not exceed 8 lozenges in 24 hours.
Children aged 3 years and older : dosage should be reduced in children. Maximum 6 lozenges in 24 hours. Tyrozets are not recommended for children under the age of three years.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/23955154
MIC90 of tyrothricin against methicillin-resistant Staphylococcus aureus isolates was 4 ug/ml
| Substance Class |
Mixture
Created
by
admin
on
Edited
Mon Mar 31 21:46:29 GMT 2025
by
admin
on
Mon Mar 31 21:46:29 GMT 2025
|
| Record UNII |
877376V2XW
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EPA PESTICIDE CODE |
6311
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
||
|
WHO-ATC |
S01AA05
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
||
|
WHO-VATC |
QD06AX08
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
||
|
WHO-ATC |
R02AB02
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
||
|
WHO-VATC |
QR02AB02
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
||
|
WHO-VATC |
QS01AA05
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
||
|
WHO-ATC |
D06AX08
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
||
|
NCI_THESAURUS |
C258
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C152789
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY | |||
|
SUB05029MIG
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY | |||
|
m11293
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY | Merck Index | ||
|
1404-88-2
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY | |||
|
DB13503
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY | |||
|
100000092138
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY | |||
|
10968
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY | RxNorm | ||
|
4739
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY | |||
|
757363
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY | |||
|
TYROTHRICIN
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY | |||
|
1344
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY | |||
|
877376V2XW
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY | |||
|
D014449
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY | |||
|
DTXSID4045846
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY | |||
|
CHEMBL577736
Created by
admin on Mon Mar 31 21:46:30 GMT 2025 , Edited by admin on Mon Mar 31 21:46:30 GMT 2025
|
PRIMARY |
All of the following components must be present:
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |